Please activate JavaScript!
Please install Adobe Flash Player, click here for download


32. Jen K.Y., Cheung V.G., 2003. Transcriptional response of lymphoblastoid cells to ionizing radiation. Genome Res. 13:2092–2100. 33. Joy D.A., Feng X., Mu J., Furuya T., Chotivanich K., Krettli A.U., Ho M., Wang A., White N.J., Suh E., Beerli P., Su X.Z., 2003. Early origin and recent expansion of Plasmodium falciparum. Science 300:318–321. 34. Kaufmann D.E., Munoz M., Bleiber G., Fleury S., Lotti B., Martinez R., Piechler W., Meylan P., Telenti A., 2000. Virological an immunological characteristics of HIV treatment failure. AIDS 14:1–8. 35. Kaufmann D.E., Pantaleo G., Sudre P., Telenti A., for the Swiss HIV Cohort Study, 1998. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 351:723–724. 36. Korber B., Muldoon M., Theiler J., Gao F., Gupta R., Lapedes A., Hahn B.H., Wolinsky S., Bhattacharya T., 2000. Timing the ancestor of the HIV-1 pandemic strains. Science 288:1789–1796. 37. Lecossier D., Bouchonnet F., Clavel F., Hance A.J., 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112. 38. Lee K., Kewalramani V.N., 2004. In defense of the cell: TRIM5alpha interception of mammalian retroviruses. Proc. Natl. Acad. Sci. U. S. A 101:10496–10497. 39. Leslie A.J., Pfafferott K.J., Chetty P., Draenert R., Addo M.M., Feeney M., Tang Y., Holmes E.C., Allen T., Prado J.G., Altfeld M., Brander C., Dixon C., Ramduth D., Jeena P., Thomas S.A., St John A., Roach T.A., Kupfer B., Luzzi G., Edwards A., Taylor G., Lyall H., Tudor-Williams G., Novelli V., Martinez-Picado J., Kiepiela P., Walker B.D., Goulder P.J., 2004. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10:282–289. 40. Lieberman J., 2002. Defying death – HIV mutation to evade cytotoxic T lymphocytes. N. Engl. J. Med. 347:1203–1204. 41. Lindesmith L., Moe C., Marionneau S., Ruvoen N., Jiang X., Lindblad L., Stewart P., LePendu J., Baric R., 2003. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 9:548–553. 42. Mammano F., Petit C., Clavel F., 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients. J Virol 72:7632–7637. 28